Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

Retrovirology

Volumn 7, Issue , 2010, Pages

  Adamson, Catherine S ^a,c   Sakalian, Michael ^b   Salzwedel, Karl ^b   Freed, Eric O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Panacos Pharmaceuticals   (United States)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVIRIMAT; CAPSID PROTEIN; CAPSID SPACER PEPTIDE 1; GAG PROTEIN; GAG SPACER PROTEIN 1; SPACER PEPTIDE 1 Q6A; SPACER PEPTIDE 1 Q6H; SPACER PEPTIDE 1 T8 DELTA; SPACER PEPTIDE 1 T8A; SPACER PEPTIDE 1 V7A; SPACER PEPTIDE 1 V7M; UNCLASSIFIED DRUG; 3-O-(3',3'-DIMETHYLSUCCINYL)BETULINIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; SUCCINIC ACID DERIVATIVE; TRITERPENE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; POINT MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENE DELETION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; POLYMORPHISM, GENETIC; SEQUENCE DELETION; SUCCINATES; TRITERPENES;

EID: 77950929797     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-36     Document Type: Article

References (37)

1. Adamson CS, Salzwedel K, Freed EO. Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets 2009, 13:895-908. 10.1517/14728220903039714, 2737327, 19534569.
2. Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol 2008, 18:203-217. 10.1016/j.sbi.2008.02.001, 2819415, 18406133.
3. Vogt VM. Proteolytic processing and particle maturation. Curr Top Microbiol Immunol 1996, 214:95-131.
4. Krausslich HG, Schneider H, Zybarth G, Carter CA, Wimmer E. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol 1988, 62:4393-4397. 253881, 3050149.
5. Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW, Venkatesan S. The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J Virol 1988, 62:3993-4002. 253827, 3262776.
6. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, Hutchison CA, Loeb DD, Swanstrom R. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 1989, 5:577-591. 10.1089/aid.1989.5.577, 2692658.
7. Tritch RJ, Cheng YE, Yin FH, Erickson-Viitanen S. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol 1991, 65:922-930. 239833, 1987379.
8. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994, 68:8017-8027. 237265, 7966591.
9. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998, 72:2846-2854. 109729, 9525604.
10. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003, 100:13555-13560. 10.1073/pnas.2234683100, 263852, 14573704.
11. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C, Chen CH. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004, 78:922-929. 10.1128/JVI.78.2.922-929.2004, 368845, 14694123.
12. Zhou J, Chen CH, Aiken C. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology 2004, 1:15. 10.1186/1742-4690-1-15, 479704, 15225375.
13. Aiken C, Chen CH. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med 2005, 11:31-36. 10.1016/j.molmed.2004.11.001, 15649820.
14. Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev 2007, 9:162-172.
15. Martin DE, Salzwedel K, Allaway GP. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother 2008, 19:107-113.
16. Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS ONE 2007, 2:e1251. 10.1371/journal.pone.0001251, 2080775, 18043758.
17. Martin DE, Blum R, Doto J, Galbraith H, Ballow C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet 2007, 46:589-598. 10.2165/00003088-200746070-00004, 17596104.
18. Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, Smith PC, Ballow C. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007, 51:3063-3066. 10.1128/AAC.01391-06, 2043192, 17576843.
19. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007, 51:3574-3581. 10.1128/AAC.00152-07, 2043264, 17638699.
20. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, Salzwedel K, Allaway G. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther 2008, 13:A10.
21. Castillo A, Adamson C, Doto J, Yunus A, Wild C, Martin D, Allaway G, Freed E, Salzwedel K. Genotypic analysis of the Gag-SP1 cleavage site in patients receiving the maturation inhibtor PA-457. Antivir Ther 2006, 11:S37.
22. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006, 80:10957-10971. 10.1128/JVI.01369-06, 1642185, 16956950.
23. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother 2009, 53:2185-2188. 10.1128/AAC.01650-08, 2681549, 19223634.
24. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 2009, 83:4884-4894. 10.1128/JVI.02659-08, 2682084, 19279107.
25. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291. 253077, 3016298.
26. Kuiken C, Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Wolinsky S, Korber B. HIV Sequence Compendium 2009 2009, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, LA-UR 09-03280.
27. Freed EO, Martin MA. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol 1994, 68:2503-2512. 236728, 8139032.
28. Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 2006, 356:217-224. 10.1016/j.virol.2006.07.023, 16930665.
29. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864. 109730, 9525605.
30. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905. 10.1128/AAC.46.6.1896-1905.2002, 127242, 12019106.
31. Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. Aids 2007, 21:871-873. 10.1097/QAD.0b013e3280b079d9, 17415044.
32. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007, 54:367-374. 10.1016/j.jinf.2006.06.012, 16875739.
33. Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 2006, 80:12095-12101. 10.1128/JVI.01626-06, 1676313, 17035324.
34. Zhou J, Huang L, Hachey DL, Chen CH, Aiken C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem 2005, 280:42149-42155. 10.1074/jbc.M508951200, 16251182.
35. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS, Lee KH. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994, 57:243-247. 10.1021/np50104a008, 8176401.
36. Kiernan RE, Ono A, Englund G, Freed EO. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 1998, 72:4116-4126. 109641, 9557701.
37. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988, 85:9580-9584. 10.1073/pnas.85.24.9580, 282803, 2849111.